Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Liabilities (2016 - 2025)

Historic Total Liabilities for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $7.5 million.

  • China Pharma Holdings' Total Liabilities rose 797.76% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 797.76%. This contributed to the annual value of $7.1 million for FY2024, which is 2079.92% down from last year.
  • Per China Pharma Holdings' latest filing, its Total Liabilities stood at $7.5 million for Q3 2025, which was up 797.76% from $7.3 million recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Total Liabilities peaked at $16.6 million during Q4 2021, and registered a low of $6.9 million during Q2 2024.
  • Moreover, its 5-year median value for Total Liabilities was $11.3 million (2021), whereas its average is $10.7 million.
  • In the last 5 years, China Pharma Holdings' Total Liabilities surged by 2683.06% in 2021 and then tumbled by 3963.26% in 2024.
  • Over the past 5 years, China Pharma Holdings' Total Liabilities (Quarter) stood at $16.6 million in 2021, then fell by 18.87% to $13.5 million in 2022, then tumbled by 33.2% to $9.0 million in 2023, then fell by 20.8% to $7.1 million in 2024, then rose by 4.92% to $7.5 million in 2025.
  • Its last three reported values are $7.5 million in Q3 2025, $7.3 million for Q2 2025, and $7.2 million during Q1 2025.